Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
functional respiratory capacity, High-resolution computed tomography, GSK2269557, acute exacerbation of COPD, lung capacity
Brief summary
The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD). Additionally study will also assess safety, tolerability and pharmacokinetic data. The total duration of the study will be 13-14 weeks including screening, treatment period and a follow up visit. Subjects will receive once daily study treatment administration starting on Day 1. Study is planned to recruit approximately 120 subjects such that approximately 100 subjects complete the study.
Interventions
DRUGGSK2269557
Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
DRUGPlacebo
Dry powder for inhalation via DISKUS 'device'
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Between 40 and 80 years of age inclusive, at the time of signing the informed consent * The subject has a confirmed and established diagnosis of COPD, as defined by the global initiative for chronic Obstructive Lung Disease (GOLD) guidelines for at least 6 months prior to entry. * The subject has a post-bronchodilator FEV1/Forced Vital Capacity (FVC) \< 0.7 and FEV1 \<= 80 % of predicted (Predictions should be according to the European Community of Coal and Steel \[ECCS\] equations), documented in the last 5 years. * Disease severity: Acute exacerbation of COPD requiring an escalation in therapy to include corticosteroid and antibiotics. Acute exacerbation to be confirmed by an experienced physician and represent a recent change in at least two major and one minor symptoms, one major and two minor symptoms, or all 3 major symptoms. Major symptoms: subjective increase in dyspnea, increase in sputum volume, and change in sputum colour. Minor symptoms: cough, wheeze and sore throat. * The subject is a smoker or an ex-smoker with a smoking history of at least 10 pack years (pack years = \[cigarettes per day smoked/20 x number of years smoked\]) * Body weight \>= 45 kilogram (kg) and body mass index (BMI) within the range 18 - 32 kg/metered squared (m\^2) (inclusive). * Male * Female subject : is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin \[hCG\] test), not lactating, and at least one of the following conditions applies: Non-reproductive potential defined as: Pre-menopausal females with one of the following: documented tubal ligation, documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, hysterectomy and documented bilateral oophorectomy. Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone \[FSH\] and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. Reproductive potential and agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication and until completion of the follow-up visit. GlaxoSmithKline (GSK) Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP): Contraceptive subdermal implant that meets the standard operating procedure (SOP) effectiveness criteria including a \<1% rate of failure per year, as stated in the product label. Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a \<1% rate of failure per year, as stated in the product label. Oral Contraceptive, either combined or progestogen alone. Injectable progestogen. Contraceptive vaginal ring. Percutaneous contraceptive patches. Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject. Male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository). * Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until after the completion of the follow up visit. Vasectomy with documentation of azoospermia. Male condom plus partner use of one of the contraceptive options below: Contraceptive subdermal implant that meets the SOP effectiveness criteria including a \<1% rate of failure per year, as stated in the product label. Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a \<1% rate of failure per year, as stated in the product label. Oral Contraceptive, either combined or progestogen alone or injectable progestogen. Contraceptive vaginal ring. Percutaneous contraceptive patches. These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in the study protocol.
Exclusion criteria
* To avoid recruitment of subjects with a severe COPD exacerbation, the presence of any one of the following severity criteria will render the subject ineligible for inclusion in the study: Need for invasive mechanical ventilation (short term (\< 48hour) Non-invasive Ventilation (NIV) or Continuous Positive Airway Pressure \[CPAP\] is acceptable). Haemodynamic instability or clinically significant heart failure. Confusion. * Subjects who have a history or current medical conditions or diseases that are not well controlled and, which as judged by the Investigator, may affect subject safety or influence the outcome of the study. (Note: Patients with adequately treated and well controlled concurrent medical conditions \[e.g. hypertension or non-insulin dependent diabetes mellitus\] are permitted to be entered into the study). * Subject has a diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, pulmonary fibrosis, asthma or any other respiratory condition that might, in the opinion of the investigator, compromise the safety of the subject or affect the interpretation of the results. * Alanine aminotransferase \>2x upper limit of normal (ULN) and bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | Baseline, Day 12 and Day 28 | siVaw is a measure of the volume in an individual's airway corrected for their lobar volume derived from the high resolution computed tomography (HRCT). It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at longitudinal time points: Screening, Day 12 & Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 & D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For longitudinal time points and SCRD12 & SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | Baseline, Day 12 and Day 28 | iRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 & D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For SCRD12 & SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title). |
| Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | Baseline, Day 12 and Day 28 | siRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 & D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For SCRD12 & SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title). |
| Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | Baseline, Day 12 and Day 28 | Change from Baseline in lung lobar volumes was measured at functional residual volume (FRC) and total lung capacity (TLC) scan conditions. Data was collected at longitudinal time points: Day 12 & Day 28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For longitudinal time points the baseline is screening. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title). |
| Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | Baseline, Day 12 and Day 28 | Imaging trachea length and diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length and diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment | Baseline, Day 12 and Day 28 | Imaging trachea length/diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length/diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Number of Participants With Adverse Events (AE) | From start of IP through the Study Phase (84 days post-dose) (assessed up to follow-up duration of approximately 100 days) | An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were collected from the start of study treatment until the follow-up contact. |
| Number of Participants With Abnormal Hematology Parameters | Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 Days) | Hematology parameter included Hematocrit (HCT), Hemoglobin (HB), Lymphocytes (LC), Platelet Count (PC), Total Neutrophils (TN), and White Blood Cell (WBC) count at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Number of Participants With Abnormal Clinical Chemistry Parameters | Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days) | Clinical Chemistry parameters included Alanine Amino Transferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Calcium (Ca), Glucose, Potassium (K), Sodium (Na), and Total Bilirubin (TBL) at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Number of Participants With Abnormal Vital Signs | Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days) | Vital signs included high and low diastolic and systolic blood presure (BP), and high and low heart rate (HR). Vital signs outside the range of potential clinical importance are presented at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline . Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days) | 12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF). Clinically non-significant (CN) and Clinically significant (CS) abnormal ECG measurements are presented for Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Day 1 Plasma Concentration up to 24 Hours (Hrs) Post-dose | Pre-dose, 5 min, 3 hrs and 24 hrs | Plasma samples were collected at pre-dose, 5 minutes (min), 3 hrs, and 24 hrs post-dose on Day 1. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Pharmacokinetic (PK) Population: all participants in the Safety Population for whom a PK sample was obtained and analyzed. Safety Population comprises of all participants who were randomized. |
| Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | Baseline, Day 12 and Day 28 | iVaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. Data was collected at longitudinal time points: Screening, Day 12 & Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 & D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For longitudinal time points and SCRD12 & SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title). |
| Changes From Baseline in Forced Expiratory Volume in One Second (FEV1) Measured Daily | Baseline, Day 28, and Day 84 | FEV1 is the volume of air that can forcibly be blown out in one second. A triplicate FEV1 measurement were taken daily in the morning before dose administration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Changes From Baseline in Peak Expiratory Flow (PEF) Measured Daily | Baseline, Day 28, and Day 84 | PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment | Baseline, Day 28 and Day 84 | DLco is diffusing capacity o f the lungs for carbon monoxide and is defined as the extent to which oxygen passes from the air sacs of the lungs into the blood. KCO is the carbon monoxide transfer coefficient. It is an index of the efficiency of alveolar transfer of carbon monoxide. Baseline is defined as the assessment on Day 2 and percent change from Baseline is the post-Baseline value minus Baseline value/100. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Change From Baseline in Total Lung Capacity (TLC) After 28 Days and After 84 Days of Treatment | Baseline, Day 28 and Day 84 | TLC is the maximum amount of air that can fill the lungs. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval. |
| Change From Baseline in Residual Volume After 28 Days and After 84 Days of Treatment | Baseline, Day 28 and Day 84 | Residual volume is a lung volume representing the amount of air left in the lungs after a forced exhalation. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval. |
| Change From Baseline in Functional Residual Capacity After 28 Days and After 84 Days of Treatment | Baseline, Day 28 and Day 84 | Functional residual capacity is the volume of air present in the lungs at the end of passive expiration. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Change From Baseline in Specific Resistance (sRaw) After 28 Days and After 84 Days of Treatment | Baseline, Day 28 and Day 84 | sRaw is the measure of specific resistance. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Change From Baseline in Specific Conductance (sGaw) After 28 Days and After 84 Days of Treatment | Baseline, Day 28 and Day 84 | Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).Note: values mentioned as 95% confidence interval below are in fact values of 95% Credible Interval. |
| Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Baseline, Day 28 and Day 84 | The chronic obstructive pulmonary disease (COPD) assessement test (CAT) and Modified Medical Research Council (MMRC) Dyspnea Scale were completed at the indicated timepoints: Baseline, Day 28 and Day 84. CAT and MMRC scales are prestned as: 1.I never cough/I cough all the time 2.I have no phelgm in my chest at all/My chest is completely full of phelgm 3. My chest does not feel tight at all/My chest feels very tight 4.Walk up hilll or stairs not breathless/Walk up hill or stairs very breathless 5. Not limited doing any home activities/Very limited doing any home activities 6. Confident leaving home/No confident leaving home 7. I sleep soundly/I don't sleep soundly because of my lung condition and 8. I have lots of energy/I have no energy at all. Baseline is defined as the assessment on Day 1. Score 0 indicates not troubled with breathlessness to 4:too breathless. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
| Number of Participants With Treatment Failures | 13 weeks | Treatment failure types are presented as: recurrent exacerbations, prolonged treatment of current exacerbation (beyond 14 days), additional treatment with systemic / oral corticosteroids and / or antibiotics, and requirement for invasive mechanical ventilation. |
| Trough Concentration After 12 Days, 28 Days, 56 Days and 84 Days of Treatment | Pre-dose Day 12, Day 28, Day 56, and Day 84 | Trough concentrations are presented for Pre-dose Day 12, Pre-dose Day 28, Pre-dose Day 56, and Pre-dose Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). |
Countries
Belgium, Denmark, Netherlands, Romania, Russia
Participant flow
Recruitment details
The study consisted of a screening visit, a 12-week treatment period, and a 1-2 week post-treatment follow-up. The total duration of the study was 13-14 weeks including the screening visit.
Pre-assignment details
Approximately 120 participants with an acute exacerbation of chronic obstructive pulmonary disease (COPD) were randomized (1:1) to GSK 2269557 1000 micrograms (µg) and placebo such that approximately 100 participants complete the study. Participants were also stratified by whether they were willing and able to provide sputum samples at screening.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days. | 63 |
| GSK2269557 1000 mcg Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days. | 63 |
| Total | 126 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 5 | 5 |
| Overall Study | Lost to Follow-up | 2 | 0 |
| Overall Study | Met Protocol Defined Stopping Criteria | 1 | 0 |
| Overall Study | Physician Decision | 2 | 1 |
| Overall Study | Withdrawal by Subject | 4 | 2 |
Baseline characteristics
| Characteristic | GSK2269557 1000 mcg | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 65.6 Years STANDARD_DEVIATION 7.14 | 65.2 Years STANDARD_DEVIATION 7.5 | 64.9 Years STANDARD_DEVIATION 7.88 |
| Race/Ethnicity, Customized American Indian or Alaskan Native | 1 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized White - White/Caucasian/European Heritage | 62 Participants | 125 Participants | 63 Participants |
| Sex: Female, Male Female | 17 Participants | 34 Participants | 17 Participants |
| Sex: Female, Male Male | 46 Participants | 92 Participants | 46 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 15 / 63 | 31 / 63 |
| serious Total, serious adverse events | 10 / 63 | 8 / 63 |
Outcome results
Primary
Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28
siVaw is a measure of the volume in an individual's airway corrected for their lobar volume derived from the high resolution computed tomography (HRCT). It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at longitudinal time points: Screening, Day 12 & Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 & D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For longitudinal time points and SCRD12 & SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).
Time frame: Baseline, Day 12 and Day 28
Population: Intention to Treat (ITT) Population excluding the subject with a pacemaker.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RUL; D12 , n =58, 57 | 1.048 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.979 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RUL; D28 , n =56, 57 | 1.045 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Upper; D28 , n =56, 58 | 0.918 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LUL; D12 , n=58, 59 | 1.043 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RLL; D28 , n =55, 58 | 0.871 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LUL; D28 , n =56, 59 | 1.078 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Lower; D12 , n=54, 59 | 0.989 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RML; D12 , n =57, 58 | 1.087 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.952 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RML; D28 , n=56, 58 | 1.084 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Lower; D28 , n =55, 58 | 0.952 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RLL; D12 , n =58, 59 | 1.038 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RML; D12 , n =52, 58 | 0.956 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RLL; D28 , n =56, 59 | 1.014 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region;Central; D12 , n =56, 59 | 0.969 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LLL; D12 , n =57, 59 | 1.074 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 0.973 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LLL; D28 ,n =55, 59 | 1.075 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal;Region; Central; D28 , n=56, 58 | 0.992 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =58, 57 | 1.040 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LLL; D12 , n =53, 58 | 1.051 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 57 | 1.020 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Distal; D12 , n =56, 59 | 0.963 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =55, 56 | 0.971 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =52, 58 | 0.924 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =58, 59 | 1.022 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Distal D28 , n =56, 58 | 0.939 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 59 | 1.035 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RUL; D28 , n =56, 56 | 0.983 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =55, 58 | 1.007 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region;Total; D12, n =56, 59 | 0.970 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =57, 58 | 1.029 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 57 | 0.927 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 58 | 1.020 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Total; D28 ,n =56, 58 | 0.989 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; D12D28 , n =55, 57 | 0.980 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LLL; D28 ,n =54, 58 | 1.000 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =58, 59 | 1.022 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 0.989 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 59 | 0.984 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 56 | 0.927 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =55, 58 | 0.962 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.962 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =57, 59 | 1.024 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RML; D28 , n=53, 57 | 0.853 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 59 | 1.025 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 0.967 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; D12D28 , n =54, 58 | 0.984 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59 | 0.987 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal;Region; Upper; D12 , n =58, 59 | 1.031 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59 | 1.019 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Upper; D28 , n =56, 59 | 1.046 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 57 | 1.049 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Lower; D12 , n=58, 59 | 1.051 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58 | 1.002 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Lower; D28 , n =56, 59 | 1.037 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58 | 0.972 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region;Central; D12 , n =58, 59 | 1.001 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57 | 0.953 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal;Region; Central; D28 , n=56, 59 | 1.006 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LUL; D28 , n =56, 58 | 0.893 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Distal; D12 , n =58, 59 | 1.043 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 0.988 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Distal D28 , n =56, 59 | 1.039 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57 | 0.920 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region;Total; D12, n =58, 59 | 1.009 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 1.002 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Total; D28 ,n =56, 59 | 1.005 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 56 | 0.999 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =58, 59 | 1.028 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 0.998 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 59 | 1.021 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58 | 1.031 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; D12D28 ,n =55, 58 | 0.985 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 0.998 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =58, 59 | 1.021 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RLL; D12 , n =54, 59 | 0.908 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 59 | 0.996 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.984 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; D12D28 ,n =55, 58 | 0.972 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58 | 1.034 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Central; SCRD12 ,n =58, 59 | 1.000 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 0.963 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 59 | 1.005 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 55 | 0.931 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region Central; D12D28 ,n =55, 58 | 1.004 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 0.989 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =58, 59 | 1.025 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56 | 0.978 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 59 | 1.008 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 1.002 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Distal; D12D28 , n =55, 58 | 0.978 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LUL; D12 , n=56, 59 | 0.975 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Total; SCRD12 , n =58, 59 | 1.005 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | Trimmed;Region;Total; D12D28 , n =53, 57 | 0.995 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 59 | 1.004 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal;Region; Upper; D12 , n =56, 59 | 0.952 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed;Region;Total; D12D28 , n =55, 58 | 0.997 Milliliter/Liter (mL/L) |
| Placebo | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RUL; D12 , n =54, 57 | 1.033 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed;Region;Total; D12D28 , n =55, 58 | 1.000 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RUL; D12 , n =54, 57 | 1.052 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RUL; D28 , n =56, 56 | 1.075 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LUL; D12 , n=56, 59 | 1.000 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LUL; D28 , n =56, 58 | 1.090 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RML; D12 , n =52, 58 | 0.871 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RML; D28 , n=53, 57 | 1.006 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RLL; D12 , n =54, 59 | 1.115 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RLL; D28 , n =55, 58 | 1.167 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LLL; D12 , n =53, 58 | 1.087 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LLL; D28 ,n =54, 58 | 1.199 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 57 | 1.002 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 56 | 0.993 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 55 | 0.995 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 1.012 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 1.018 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 1.014 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =52, 58 | 0.977 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 57 | 0.967 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 56 | 1.023 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59 | 1.000 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58 | 1.014 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57 | 1.015 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58 | 1.050 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58 | 1.064 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56 | 1.055 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal;Region; Upper; D12 , n =56, 59 | 1.004 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Upper; D28 , n =56, 58 | 1.066 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Lower; D12 , n=54, 59 | 1.065 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Lower; D28 , n =55, 58 | 1.150 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region;Central; D12 , n =56, 59 | 1.021 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal;Region; Central; D28 , n=56, 58 | 1.002 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Distal; D12 , n =56, 59 | 1.027 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Distal D28 , n =56, 58 | 1.098 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region;Total; D12, n =56, 59 | 1.018 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Total; D28 ,n =56, 58 | 1.009 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 1.001 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 1.007 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 1.011 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59 | 1.028 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58 | 1.039 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57 | 1.008 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 1.022 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 0.999 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 0.977 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 1.009 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 1.021 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 1.019 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 1.019 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 1.000 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | Trimmed;Region;Total; D12D28 , n =53, 57 | 0.982 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RUL; D12 , n =58, 57 | 0.976 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RUL; D28 , n =56, 57 | 0.979 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LUL; D12 , n=58, 59 | 1.007 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LUL; D28 , n =56, 59 | 1.027 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RML; D12 , n =57, 58 | 0.894 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RML; D28 , n=56, 58 | 0.903 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RLL; D12 , n =58, 59 | 0.906 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RLL; D28 , n =56, 59 | 0.948 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LLL; D12 , n =57, 59 | 0.934 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LLL; D28 ,n =55, 59 | 0.993 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =58, 57 | 0.988 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 57 | 0.981 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =55, 56 | 1.002 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =58, 59 | 1.001 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 59 | 0.991 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =55, 58 | 1.002 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =57, 58 | 0.934 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 58 | 0.932 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; D12D28 , n =55, 57 | 1.008 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =58, 59 | 0.932 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 59 | 0.944 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =55, 58 | 1.027 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =57, 59 | 0.967 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 59 | 0.972 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; D12D28 , n =54, 58 | 1.017 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal;Region; Upper; D12 , n =58, 59 | 0.983 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Upper; D28 , n =56, 59 | 0.995 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Lower; D12 , n=58, 59 | 0.924 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Lower; D28 , n =56, 59 | 0.974 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region;Central; D12 , n =58, 59 | 0.991 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal;Region; Central; D28 , n=56, 59 | 0.992 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Distal; D12 , n =58, 59 | 0.949 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Distal D28 , n =56, 59 | 0.982 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region;Total; D12, n =58, 59 | 0.982 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Total; D28 ,n =56, 59 | 0.988 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =58, 59 | 0.992 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 59 | 0.984 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; D12D28 ,n =55, 58 | 1.003 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =58, 59 | 0.954 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 59 | 0.960 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; D12D28 ,n =55, 58 | 1.018 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Central; SCRD12 ,n =58, 59 | 0.997 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 59 | 0.995 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region Central; D12D28 ,n =55, 58 | 0.998 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =58, 59 | 0.972 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 59 | 0.972 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Distal; D12D28 , n =55, 58 | 1.011 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Total; SCRD12 , n =58, 59 | 0.991 Milliliter/Liter (mL/L) |
| GSK2269557 1000 mcg | Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 59 | 0.989 Milliliter/Liter (mL/L) |
p-value: 60.6695% CI: [0.85, 1.25]Bayesian repeated measures model
p-value: 95.2195% CI: [0.97, 1.47]Bayesian repeated measures model
p-value: 74.2995% CI: [0.88, 1.28]Bayesian repeated measures model
p-value: 99.4895% CI: [1.06, 1.58]Bayesian repeated measures model
p-value: 13.9895% CI: [0.66, 1.13]Bayesian repeated measures model
p-value: 97.9295% CI: [1.01, 1.62]Bayesian repeated measures model
p-value: 80.2495% CI: [0.84, 1.54]Bayesian repeated measures model
p-value: 97.7995% CI: [1.01, 1.66]Bayesian repeated measures model
p-value: 51.2795% CI: [0.81, 1.25]Bayesian repeated measures model
p-value: 90.6695% CI: [0.93, 1.42]Bayesian repeated measures model
p-value: 54.8995% CI: [0.9, 1.12]Bayesian repeated measures model
p-value: 94.4595% CI: [0.98, 1.24]Bayesian repeated measures model
p-value: 94.0995% CI: [0.98, 1.21]Bayesian repeated measures model
p-value: 62.9595% CI: [0.91, 1.14]Bayesian repeated measures model
p-value: 96.8695% CI: [0.99, 1.26]Bayesian repeated measures model
p-value: 94.1695% CI: [0.98, 1.2]Bayesian repeated measures model
p-value: 48.9995% CI: [0.86, 1.15]Bayesian repeated measures model
p-value: 94.5195% CI: [0.98, 1.28]Bayesian repeated measures model
p-value: 94.5995% CI: [0.97, 1.31]Bayesian repeated measures model
p-value: 61.2795% CI: [0.86, 1.23]Bayesian repeated measures model
p-value: 96.6395% CI: [0.99, 1.34]Bayesian repeated measures model
p-value: 94.0295% CI: [0.97, 1.29]Bayesian repeated measures model
p-value: 53.2495% CI: [0.87, 1.17]Bayesian repeated measures model
p-value: 70.8495% CI: [0.91, 1.19]Bayesian repeated measures model
p-value: 74.1595% CI: [0.92, 1.19]Bayesian repeated measures model
p-value: 65.4395% CI: [0.87, 1.24]Bayesian repeated measures model
p-value: 97.1595% CI: [0.99, 1.42]Bayesian repeated measures model
p-value: 63.9995% CI: [0.81, 1.34]Bayesian repeated measures model
p-value: 91.9995% CI: [0.94, 1.41]Bayesian repeated measures model
p-value: 76.8195% CI: [0.94, 1.14]Bayesian repeated measures model
p-value: 67.0195% CI: [0.95, 1.09]Bayesian repeated measures model
p-value: 63.9195% CI: [0.85, 1.27]Bayesian repeated measures model
p-value: 96.4795% CI: [0.99, 1.42]Bayesian repeated measures model
p-value: 72.1795% CI: [0.93, 1.14]Bayesian repeated measures model
p-value: 74.3895% CI: [0.95, 1.11]Bayesian repeated measures model
p-value: 53.8595% CI: [0.9, 1.12]Bayesian repeated measures model
p-value: 95.0295% CI: [0.98, 1.23]Bayesian repeated measures model
p-value: 92.2795% CI: [0.97, 1.18]Bayesian repeated measures model
p-value: 54.6595% CI: [0.88, 1.16]Bayesian repeated measures model
p-value: 87.9395% CI: [0.95, 1.23]Bayesian repeated measures model
p-value: 77.5795% CI: [0.92, 1.19]Bayesian repeated measures model
p-value: 77.0795% CI: [0.95, 1.11]Bayesian repeated measures model
p-value: 78.4295% CI: [0.96, 1.1]Bayesian repeated measures model
p-value: 44.1595% CI: [0.93, 1.06]Bayesian repeated measures model
p-value: 52.7995% CI: [0.89, 1.13]Bayesian repeated measures model
p-value: 94.5195% CI: [0.98, 1.24]Bayesian repeated measures model
p-value: 93.1695% CI: [0.98, 1.19]Bayesian repeated measures model
p-value: 73.795% CI: [0.95, 1.11]Bayesian repeated measures model
p-value: 81.0495% CI: [0.96, 1.1]Bayesian repeated measures model
p-value: 52.5895% CI: [0.94, 1.07]Bayesian repeated measures model
p-value: 15.8595% CI: [0.86, 1.05]Bayesian repeated measures model
p-value: 48.6995% CI: [0.9, 1.11]Bayesian repeated measures model
p-value: 52.2595% CI: [0.9, 1.13]Bayesian repeated measures model
p-value: 66.4895% CI: [0.91, 1.16]Bayesian repeated measures model
p-value: 9.1295% CI: [0.72, 1.06]Bayesian repeated measures model
p-value: 16.9595% CI: [0.78, 1.09]Bayesian repeated measures model
p-value: 0.8995% CI: [0.75, 1.05]Bayesian repeated measures model
p-value: 50.495% CI: [0.86, 1.17]Bayesian repeated measures model
p-value: 7.4495% CI: [0.76, 1.04]Bayesian repeated measures model
p-value: 56.3595% CI: [0.87, 1.18]Bayesian repeated measures model
p-value: 4.0395% CI: [0.87, 1.01]Bayesian repeated measures model
p-value: 24.7995% CI: [0.89, 1.06]Bayesian repeated measures model
p-value: 77.0895% CI: [0.95, 1.12]Bayesian repeated measures model
p-value: 23.0795% CI: [0.89, 1.05]Bayesian repeated measures model
p-value: 18.5895% CI: [0.88, 1.05]Bayesian repeated measures model
p-value: 44.9495% CI: [0.92, 1.08]Bayesian repeated measures model
p-value: 2.2195% CI: [0.8, 1]Bayesian repeated measures model
p-value: 6.0995% CI: [0.83, 1.02]Bayesian repeated measures model
p-value: 66.695% CI: [0.92, 1.13]Bayesian repeated measures model
p-value: 3.2395% CI: [0.81, 1.01]Bayesian repeated measures model
p-value: 20.8395% CI: [0.86, 1.07]Bayesian repeated measures model
p-value: 87.695% CI: [0.96, 1.16]Bayesian repeated measures model
p-value: 7.995% CI: [0.84, 1.03]Bayesian repeated measures model
p-value: 23.3995% CI: [0.87, 1.07]Bayesian repeated measures model
p-value: 76.1695% CI: [0.95, 1.12]Bayesian repeated measures model
p-value: 22.5495% CI: [0.87, 1.06]Bayesian repeated measures model
p-value: 58.1795% CI: [0.91, 1.12]Bayesian repeated measures model
p-value: 6.2295% CI: [0.76, 1.03]Bayesian repeated measures model
p-value: 55.8595% CI: [0.88, 1.17]Bayesian repeated measures model
p-value: 25.4495% CI: [0.96, 1.02]Bayesian repeated measures model
p-value: 18.1595% CI: [0.96, 1.02]Bayesian repeated measures model
p-value: 8.1295% CI: [0.82, 1.04]Bayesian repeated measures model
p-value: 57.3995% CI: [0.9, 1.13]Bayesian repeated measures model
p-value: 1095% CI: [0.93, 1.02]Bayesian repeated measures model
p-value: 29.8895% CI: [0.95, 1.03]Bayesian repeated measures model
p-value: 12.6395% CI: [0.89, 1.03]Bayesian repeated measures model
p-value: 32.2995% CI: [0.91, 1.06]Bayesian repeated measures model
p-value: 69.9295% CI: [0.95, 1.1]Bayesian repeated measures model
p-value: 6.195% CI: [0.84, 1.02]Bayesian repeated measures model
p-value: 33.6395% CI: [0.89, 1.08]Bayesian repeated measures model
p-value: 86.0795% CI: [0.97, 1.13]Bayesian repeated measures model
p-value: 41.3895% CI: [0.96, 1.03]Bayesian repeated measures model
p-value: 24.8895% CI: [0.96, 1.02]Bayesian repeated measures model
p-value: 29.8995% CI: [0.97, 1.02]Bayesian repeated measures model
p-value: 7.1395% CI: [0.87, 1.02]Bayesian repeated measures model
p-value: 32.9195% CI: [0.9, 1.07]Bayesian repeated measures model
p-value: 81.1595% CI: [0.96, 1.11]Bayesian repeated measures model
p-value: 21.8795% CI: [0.95, 1.02]Bayesian repeated measures model
p-value: 24.4995% CI: [0.95, 1.02]Bayesian repeated measures model
p-value: 55.5295% CI: [0.97, 1.03]Bayesian repeated measures model
Secondary
Change From Baseline in Functional Residual Capacity After 28 Days and After 84 Days of Treatment
Functional residual capacity is the volume of air present in the lungs at the end of passive expiration. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Day 28 and Day 84
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Functional Residual Capacity After 28 Days and After 84 Days of Treatment | Day 28, n=52, 59 | 0.0010 L | Standard Deviation 0.86637 |
| Placebo | Change From Baseline in Functional Residual Capacity After 28 Days and After 84 Days of Treatment | Day 84, =46, 55 | -0.2219 L | Standard Deviation 1.06874 |
| GSK2269557 1000 mcg | Change From Baseline in Functional Residual Capacity After 28 Days and After 84 Days of Treatment | Day 28, n=52, 59 | -0.0919 L | Standard Deviation 0.92501 |
| GSK2269557 1000 mcg | Change From Baseline in Functional Residual Capacity After 28 Days and After 84 Days of Treatment | Day 84, =46, 55 | -0.0505 L | Standard Deviation 1.4191 |
Secondary
Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28
iRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 & D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For SCRD12 & SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).
Time frame: Baseline, Day 12 and Day 28
Population: ITT Population excluding the subject with a pacemaker.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =56, 59 | 0.843 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 57 | 1.027 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58 | 0.929 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.940 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =53, 57 | 1.152 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58 | 0.849 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.879 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 0.869 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.922 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59 | 1.100 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 1.025 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59 | 0.845 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =57, 58 | 1.076 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 0.842 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 59 | 0.989 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58 | 1.215 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; D12D28 , n =56, 58 | 1.102 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58 | 1.504 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =56, 59 | 0.848 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57 | 1.113 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 58 | 0.965 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.982 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =53, 57 | 1.208 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 1.104 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =55, 59 | 0.813 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57 | 1.289 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 58 | 0.958 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 1.079 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; D12D28 , n=52, 57 | 1.313 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =53, 59 | 1.022 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 0.913 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 1.033 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.958 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58 | 0.781 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 1.067 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 0.800 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =56, 59 | 0.850 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 57 | 1.039 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 58 | 0.953 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.993 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; D12D28 ,n =53, 57 | 1.269 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58 | 0.949 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 0.960 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 0.887 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 0.976 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 58 | 1.378 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 1.039 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 1.006 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 0.889 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56 | 1.051 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.945 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 1.036 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 1.189 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.937 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 0.891 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 1.000 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 0.956 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 0.934 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 1.133 Kilopascal (Kpa)*s/L |
| Placebo | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 59 | 0.908 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 0.904 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 59 | 0.948 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58 | 0.958 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 57 | 0.898 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.946 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.820 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 0.934 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =53, 59 | 0.998 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 58 | 0.886 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 57 | 1.198 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59 | 1.043 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58 | 1.044 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57 | 1.126 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58 | 0.738 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58 | 0.818 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56 | 1.012 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 0.960 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.887 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 1.127 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59 | 0.821 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58 | 0.868 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57 | 1.193 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 0.933 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 0.950 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 1.010 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 0.859 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.873 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 1.220 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 0.919 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 0.922 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 1.066 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =56, 59 | 0.978 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58 | 1.019 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =53, 57 | 0.901 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.979 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.886 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 0.894 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =57, 58 | 1.349 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 59 | 1.220 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; D12D28 , n =56, 58 | 0.988 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =56, 59 | 1.143 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 58 | 1.122 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =53, 57 | 0.927 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =55, 59 | 1.139 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 58 | 0.987 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; D12D28 , n=52, 57 | 0.829 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 1.103 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.957 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 0.885 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =56, 59 | 1.116 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 58 | 1.056 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; D12D28 ,n =53, 57 | 0.862 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 1.007 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 1.000 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 0.981 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 1.116 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.976 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 0.838 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 1.061 Kilopascal (Kpa)*s/L |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 0.989 Kilopascal (Kpa)*s/L |
p-value: 60.0795% CI: [0.66, 1.39]Bayesian repeated measures model
p-value: 51.7595% CI: [0.65, 1.53]Bayesian repeated measures model
p-value: 65.6695% CI: [0.6, 1.4]Bayesian repeated measures model
p-value: 81.6795% CI: [0.59, 1.21]Bayesian repeated measures model
p-value: 89.9895% CI: [0.51, 1.15]Bayesian repeated measures model
p-value: 43.8895% CI: [0.7, 1.51]Bayesian repeated measures model
p-value: 36.195% CI: [0.64, 1.91]Bayesian repeated measures model
p-value: 95.7495% CI: [0.47, 1.05]Bayesian repeated measures model
p-value: 50.7495% CI: [0.67, 1.48]Bayesian repeated measures model
p-value: 72.8195% CI: [0.51, 1.44]Bayesian repeated measures model
p-value: 94.4195% CI: [0.5, 1.08]Bayesian repeated measures model
p-value: 81.0795% CI: [0.55, 1.25]Bayesian repeated measures model
p-value: 69.2995% CI: [0.5, 1.51]Bayesian repeated measures model
p-value: 73.6795% CI: [0.54, 1.37]Bayesian repeated measures model
p-value: 75.8295% CI: [0.59, 1.29]Bayesian repeated measures model
p-value: 54.2295% CI: [0.69, 1.39]Bayesian repeated measures model
p-value: 66.4695% CI: [0.63, 1.35]Bayesian repeated measures model
p-value: 21.4595% CI: [0.79, 1.71]Bayesian repeated measures model
p-value: 69.9195% CI: [0.5, 1.5]Bayesian repeated measures model
p-value: 75.2995% CI: [0.57, 1.31]Bayesian repeated measures model
p-value: 44.0595% CI: [0.68, 1.58]Bayesian repeated measures model
p-value: 94.9395% CI: [0.65, 1.04]Bayesian repeated measures model
p-value: 97.1195% CI: [0.59, 1.01]Bayesian repeated measures model
p-value: 85.4195% CI: [0.7, 1.11]Bayesian repeated measures model
p-value: 54.7395% CI: [0.62, 1.53]Bayesian repeated measures model
p-value: 72.3195% CI: [0.61, 1.3]Bayesian repeated measures model
p-value: 15.0595% CI: [0.84, 1.75]Bayesian repeated measures model
p-value: 84.8795% CI: [0.68, 1.13]Bayesian repeated measures model
p-value: 92.2495% CI: [0.63, 1.08]Bayesian repeated measures model
p-value: 63.4295% CI: [0.75, 1.22]Bayesian repeated measures model
p-value: 9.0595% CI: [0.93, 1.46]Bayesian repeated measures model
p-value: 66.495% CI: [0.74, 1.22]Bayesian repeated measures model
p-value: 97.3995% CI: [0.6, 1]Bayesian repeated measures model
p-value: 16.0295% CI: [0.89, 1.42]Bayesian repeated measures model
p-value: 75.6995% CI: [0.68, 1.21]Bayesian repeated measures model
p-value: 90.2295% CI: [0.69, 1.08]Bayesian repeated measures model
p-value: 9.6495% CI: [0.91, 1.62]Bayesian repeated measures model
p-value: 20.4495% CI: [0.82, 1.61]Bayesian repeated measures model
p-value: 55.0695% CI: [0.73, 1.31]Bayesian repeated measures model
p-value: 5.2995% CI: [0.94, 1.97]Bayesian repeated measures model
p-value: 28.8295% CI: [0.77, 1.6]Bayesian repeated measures model
p-value: 9395% CI: [0.61, 1.07]Bayesian repeated measures model
p-value: 1.6495% CI: [1.03, 1.95]Bayesian repeated measures model
p-value: 50.7195% CI: [0.72, 1.38]Bayesian repeated measures model
p-value: 99.5295% CI: [0.51, 0.91]Bayesian repeated measures model
p-value: 3.195% CI: [0.99, 1.51]Bayesian repeated measures model
p-value: 75.3995% CI: [0.71, 1.18]Bayesian repeated measures model
p-value: 93.2995% CI: [0.68, 1.05]Bayesian repeated measures model
p-value: 3.7995% CI: [0.97, 1.82]Bayesian repeated measures model
p-value: 36.7595% CI: [0.76, 1.48]Bayesian repeated measures model
p-value: 99.3295% CI: [0.56, 0.93]Bayesian repeated measures model
p-value: 18.9195% CI: [0.93, 1.2]Bayesian repeated measures model
p-value: 47.3595% CI: [0.87, 1.15]Bayesian repeated measures model
p-value: 7895% CI: [0.86, 1.07]Bayesian repeated measures model
p-value: 2.6595% CI: [1, 1.67]Bayesian repeated measures model
p-value: 58.4895% CI: [0.73, 1.29]Bayesian repeated measures model
p-value: 99.6495% CI: [0.61, 0.92]Bayesian repeated measures model
p-value: 1.995% CI: [1.01, 1.4]Bayesian repeated measures model
p-value: 63.0395% CI: [0.81, 1.16]Bayesian repeated measures model
p-value: 99.1995% CI: [0.72, 0.97]Bayesian repeated measures model
Secondary
Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28
iVaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. Data was collected at longitudinal time points: Screening, Day 12 & Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 & D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For longitudinal time points and SCRD12 & SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).
Time frame: Baseline, Day 12 and Day 28
Population: ITT Population excluding the subject with a pacemaker.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RUL; D12 , n =58, 59 | 1.057 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.954 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RUL; D28 , n =56, 59 | 1.050 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Upper; D28 , n =56, 58 | 0.898 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LUL; D12 , n=58, 59 | 1.045 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RLL; D28 , n =55, 58 | 0.850 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LUL; D28 , n =56, 59 | 1.082 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Lower; D12 , n=54, 59 | 0.965 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RML; D12 , n =58, 59 | 1.045 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.933 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RML; D28 , n=56, 59 | 1.076 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Lower; D28 , n =55, 58 | 0.931 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RLL; D12 , n =58, 59 | 1.049 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RML; D12 , n =53, 59 | 0.905 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RLL; D28 , n =56, 59 | 1.014 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region;Central; D12 , n =56, 59 | 0.945 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LLL; D12, n =57, 59 | 1.082 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 0.981 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LLL; D28 ,n =55, 59 | 1.077 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal;Region; Cetral; D28 , n=56, 58 | 0.968 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =58, 59 | 1.049 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LLL; D12 , n =53, 58 | 1.017 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 59 | 1.025 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Distal; D12 , n =56, 59 | 0.939 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =55, 58 | 0.966 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =53, 59 | 0.905 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =58, 59 | 1.024 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Distal D28 , n =56, 58 | 0.917 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 59 | 1.039 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RUL; D28 , n =56, 58 | 0.960 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =55, 58 | 1.008 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region;Total; D12 n =56, 59 | 0.946 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =58, 59 | 1.017 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 58 | 0.907 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 59 | 1.013 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Total; D28 ,n =56, 58 | 0.966 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; D12D28 , n =55, 58 | 0.974 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LLL; D28 ,n =54, 58 | 0.980 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =58, 59 | 1.032 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 0.969 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 59 | 0.983 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 57 | 0.927 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =55, 58 | 0.953 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.941 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =57, 59 | 1.032 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RML; D28 , n=53, 58 | 0.835 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 59 | 1.027 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 0.968 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; D12D28 , n =54, 58 | 0.976 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59 | 0.968 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal;Region; Upper; D12 , n =58, 59 | 1.037 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59 | 0.994 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Upper; D28 , n =56, 59 | 1.049 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 59 | 1.035 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Lower; D12 , n=58, 59 | 1.061 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58 | 0.980 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Lower; D28 , n =56, 59 | 1.037 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58 | 0.948 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region;Central; D12 , n =58, 59 | 1.006 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57 | 0.954 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal;Region; Cetral; D28 , n=56, 59 | 1.007 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LUL; D28 , n =56, 58 | 0.876 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Distal; D12 , n =58, 59 | 1.048 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 0.964 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Distal D28 , n =56, 59 | 1.041 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57 | 0.916 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region;Total; D12, n =58, 59 | 1.014 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 0.978 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Total; D28 ,n =56, 59 | 1.007 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58 | 0.976 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =58, 59 | 1.033 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 1.000 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 59 | 1.025 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58 | 0.997 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; D12D28 ,n =55, 58 | 0.983 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 0.974 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =58, 59 | 1.030 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RLL; D12 , n =54, 59 | 0.889 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 59 | 0.997 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.960 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; D12D28 ,n =55, 58 | 0.964 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58 | 1.013 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Central; SCRD12 ,n =58, 59 | 1.005 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 0.965 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 59 | 1.007 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 57 | 0.927 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region Central; D12D28 ,n =55, 58 | 1.000 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 0.965 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =58, 59 | 1.030 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56 | 0.989 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 59 | 1.010 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 0.978 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Distal; D12D28 , n =55, 58 | 0.975 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LUL; D12 , n=56, 59 | 0.951 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Total; SCRD12 , n =58, 59 | 1.010 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 0.998 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 59 | 1.006 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal;Region; Upper; D12 , n =56, 59 | 0.933 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed;Region;Total; D12D28 , n =55, 58 | 0.993 Milliliter (mL) |
| Placebo | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RUL; D12 , n =54, 59 | 1.020 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed;Region;Total; D12D28 , n =55, 58 | 1.005 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RUL; D12 , n =54, 59 | 1.058 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RUL; D28 , n =56, 58 | 1.121 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LUL; D12 , n=56, 59 | 0.999 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LUL; D28 , n =56, 58 | 1.108 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RML; D12 , n =53, 59 | 0.869 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RML; D28 , n=53, 58 | 1.013 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RLL; D12 , n =54, 59 | 1.119 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; RLL; D28 , n =55, 58 | 1.177 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LLL; D12 , n =53, 58 | 1.067 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Lobes; LLL; D28 ,n =54, 58 | 1.187 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 59 | 1.006 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58 | 1.027 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 57 | 1.018 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 1.010 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 1.035 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 1.029 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =53, 59 | 0.970 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 58 | 0.972 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 57 | 1.031 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59 | 1.004 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58 | 1.022 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57 | 1.018 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58 | 1.031 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58 | 1.054 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56 | 1.061 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal;Region; Upper; D12 , n =56, 59 | 1.000 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Upper; D28 , n =56, 58 | 1.079 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Lower; D12 , n=54, 59 | 1.058 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Lower; D28 , n =55, 58 | 1.151 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region;Central; D12 , n =56, 59 | 1.016 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal;Region; Cetral; D28 , n=56, 58 | 1.010 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Distal; D12 , n =56, 59 | 1.022 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Distal D28 , n =56, 58 | 1.107 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region;Total; D12 n =56, 59 | 1.012 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Longitudinal; Region; Total; D28 ,n =56, 58 | 1.017 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 0.997 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 1.019 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 1.025 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59 | 1.022 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58 | 1.040 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57 | 1.013 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 1.016 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 1.007 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 0.988 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 1.003 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 1.030 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 1.030 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 1.014 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 1.008 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 0.993 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RUL; D12 , n =58, 59 | 0.982 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RUL; D28 , n =56, 59 | 0.989 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LUL; D12 , n=58, 59 | 1.005 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LUL; D28 , n =56, 59 | 1.025 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RML; D12 , n =58, 59 | 0.887 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RML; D28 , n=56, 59 | 0.906 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RLL; D12 , n =58, 59 | 0.910 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; RLL; D28 , n =56, 59 | 0.956 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LLL; D12, n =57, 59 | 0.924 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Lobes; LLL; D28 ,n =55, 59 | 0.989 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =58, 59 | 0.994 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 59 | 0.987 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =55, 58 | 1.002 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =58, 59 | 0.999 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 59 | 0.989 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =55, 58 | 1.002 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =58, 59 | 0.926 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 59 | 0.935 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; D12D28 , n =55, 58 | 1.021 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =58, 59 | 0.936 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 59 | 0.952 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =55, 58 | 1.033 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =57, 59 | 0.956 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 59 | 0.968 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; D12D28 , n =54, 58 | 1.025 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal;Region; Upper; D12 , n =58, 59 | 0.981 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Upper; D28 , n =56, 59 | 0.994 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Lower; D12 , n=58, 59 | 0.921 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Lower; D28 , n =56, 59 | 0.977 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region;Central; D12 , n =58, 59 | 0.988 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal;Region; Cetral; D28 , n=56, 59 | 0.993 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Distal; D12 , n =58, 59 | 0.947 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Distal D28 , n =56, 59 | 0.983 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region;Total; D12, n =58, 59 | 0.979 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Longitudinal; Region; Total; D28 ,n =56, 59 | 0.989 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =58, 59 | 0.989 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 59 | 0.983 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; D12D28 ,n =55, 58 | 1.006 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =58, 59 | 0.951 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 59 | 0.963 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; D12D28 ,n =55, 58 | 1.025 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Central; SCRD12 ,n =58, 59 | 0.994 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 59 | 0.995 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region Central; D12D28 ,n =55, 58 | 1.003 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =58, 59 | 0.969 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 59 | 0.973 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Distal; D12D28 , n =55, 58 | 1.016 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Total; SCRD12 , n =58, 59 | 0.989 Milliliter (mL) |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 59 | 0.990 Milliliter (mL) |
p-value: 59.5595% CI: [0.84, 1.25]Bayesian repeated measures model
p-value: 94.0195% CI: [0.96, 1.46]Bayesian repeated measures model
p-value: 82.2795% CI: [0.9, 1.33]Bayesian repeated measures model
p-value: 99.2295% CI: [1.06, 1.61]Bayesian repeated measures model
p-value: 46.2495% CI: [0.75, 1.29]Bayesian repeated measures model
p-value: 98.395% CI: [1.02, 1.64]Bayesian repeated measures model
p-value: 92.695% CI: [0.92, 1.7]Bayesian repeated measures model
p-value: 99.0195% CI: [1.05, 1.81]Bayesian repeated measures model
p-value: 58.895% CI: [0.82, 1.28]Bayesian repeated measures model
p-value: 86.8295% CI: [0.91, 1.42]Bayesian repeated measures model
p-value: 67.3795% CI: [0.92, 1.14]Bayesian repeated measures model
p-value: 98.3595% CI: [1.01, 1.29]Bayesian repeated measures model
p-value: 96.8695% CI: [0.99, 1.23]Bayesian repeated measures model
p-value: 86.1895% CI: [0.95, 1.19]Bayesian repeated measures model
p-value: 98.8995% CI: [1.02, 1.31]Bayesian repeated measures model
p-value: 91.9495% CI: [0.97, 1.19]Bayesian repeated measures model
p-value: 55.3295% CI: [0.88, 1.17]Bayesian repeated measures model
p-value: 97.1795% CI: [1, 1.32]Bayesian repeated measures model
p-value: 96.5795% CI: [0.99, 1.32]Bayesian repeated measures model
p-value: 79.1395% CI: [0.9, 1.27]Bayesian repeated measures model
p-value: 99.5495% CI: [1.05, 1.42]Bayesian repeated measures model
p-value: 97.895% CI: [1, 1.3]Bayesian repeated measures model
p-value: 71.9495% CI: [0.91, 1.19]Bayesian repeated measures model
p-value: 85.395% CI: [0.94, 1.23]Bayesian repeated measures model
p-value: 82.1595% CI: [0.94, 1.19]Bayesian repeated measures model
p-value: 72.5595% CI: [0.88, 1.27]Bayesian repeated measures model
p-value: 98.4495% CI: [1.02, 1.47]Bayesian repeated measures model
p-value: 78.2495% CI: [0.86, 1.43]Bayesian repeated measures model
p-value: 96.895% CI: [0.99, 1.52]Bayesian repeated measures model
p-value: 91.1195% CI: [0.97, 1.17]Bayesian repeated measures model
p-value: 89.395% CI: [0.97, 1.13]Bayesian repeated measures model
p-value: 74.6795% CI: [0.87, 1.32]Bayesian repeated measures model
p-value: 98.2595% CI: [1.02, 1.48]Bayesian repeated measures model
p-value: 87.895% CI: [0.96, 1.18]Bayesian repeated measures model
p-value: 91.5495% CI: [0.97, 1.15]Bayesian repeated measures model
p-value: 68.8995% CI: [0.92, 1.14]Bayesian repeated measures model
p-value: 98.1995% CI: [1.01, 1.27]Bayesian repeated measures model
p-value: 94.0795% CI: [0.98, 1.19]Bayesian repeated measures model
p-value: 75.7495% CI: [0.92, 1.19]Bayesian repeated measures model
p-value: 95.8395% CI: [0.99, 1.28]Bayesian repeated measures model
p-value: 79.895% CI: [0.94, 1.17]Bayesian repeated measures model
p-value: 95.2995% CI: [0.99, 1.13]Bayesian repeated measures model
p-value: 96.2795% CI: [0.99, 1.13]Bayesian repeated measures model
p-value: 47.6295% CI: [0.94, 1.06]Bayesian repeated measures model
p-value: 71.5595% CI: [0.92, 1.15]Bayesian repeated measures model
p-value: 98.2995% CI: [1.01, 1.28]Bayesian repeated measures model
p-value: 95.0995% CI: [0.99, 1.19]Bayesian repeated measures model
p-value: 93.6895% CI: [0.98, 1.13]Bayesian repeated measures model
p-value: 96.5895% CI: [1, 1.14]Bayesian repeated measures model
p-value: 56.9995% CI: [0.95, 1.06]Bayesian repeated measures model
p-value: 13.0895% CI: [0.85, 1.04]Bayesian repeated measures model
p-value: 52.9995% CI: [0.89, 1.13]Bayesian repeated measures model
p-value: 60.7595% CI: [0.9, 1.14]Bayesian repeated measures model
p-value: 75.2395% CI: [0.92, 1.2]Bayesian repeated measures model
p-value: 28.1495% CI: [0.78, 1.14]Bayesian repeated measures model
p-value: 38.4395% CI: [0.84, 1.14]Bayesian repeated measures model
p-value: 25.2195% CI: [0.8, 1.12]Bayesian repeated measures model
p-value: 81.7395% CI: [0.91, 1.27]Bayesian repeated measures model
p-value: 9.8795% CI: [0.76, 1.06]Bayesian repeated measures model
p-value: 63.1595% CI: [0.87, 1.21]Bayesian repeated measures model
p-value: 4.0395% CI: [0.86, 1.01]Bayesian repeated measures model
p-value: 30.0395% CI: [0.89, 1.07]Bayesian repeated measures model
p-value: 80.3495% CI: [0.95, 1.13]Bayesian repeated measures model
p-value: 25.6595% CI: [0.89, 1.06]Bayesian repeated measures model
p-value: 24.3695% CI: [0.88, 1.06]Bayesian repeated measures model
p-value: 48.4595% CI: [0.91, 1.09]Bayesian repeated measures model
p-value: 1.9595% CI: [0.81, 0.99]Bayesian repeated measures model
p-value: 14.1595% CI: [0.85, 1.05]Bayesian repeated measures model
p-value: 80.6195% CI: [0.95, 1.16]Bayesian repeated measures model
p-value: 3.395% CI: [0.81, 1.01]Bayesian repeated measures model
p-value: 42.2295% CI: [0.88, 1.11]Bayesian repeated measures model
p-value: 95.2495% CI: [0.99, 1.2]Bayesian repeated measures model
p-value: 6.3895% CI: [0.83, 1.03]Bayesian repeated measures model
p-value: 28.8295% CI: [0.86, 1.09]Bayesian repeated measures model
p-value: 87.3995% CI: [0.97, 1.14]Bayesian repeated measures model
p-value: 23.2795% CI: [0.87, 1.07]Bayesian repeated measures model
p-value: 57.8295% CI: [0.9, 1.13]Bayesian repeated measures model.
p-value: 9.6795% CI: [0.77, 1.06]Bayesian repeated measures model.
p-value: 70.7395% CI: [0.89, 1.22]Bayesian repeated measures model.
p-value: 25.6195% CI: [0.95, 1.02]Bayesian repeated measures model.
p-value: 44.195% CI: [0.96, 1.03]Bayesian repeated measures model.
p-value: 10.1495% CI: [0.82, 1.04]Bayesian repeated measures model.
p-value: 62.8795% CI: [0.9, 1.16]Bayesian repeated measures model.
p-value: 11.8295% CI: [0.93, 1.02]Bayesian repeated measures model.
p-value: 51.4495% CI: [0.95, 1.05]Bayesian repeated measures model.
p-value: 9.5495% CI: [0.88, 1.03]Bayesian repeated measures model
p-value: 30.0395% CI: [0.89, 1.07]Bayesian repeated measures model
p-value: 73.0395% CI: [0.95, 1.11]Bayesian repeated measures model.
p-value: 4.6495% CI: [0.83, 1.01]Bayesian repeated measures model.
p-value: 42.1395% CI: [0.89, 1.1]Bayesian repeated measures model
p-value: 93.3395% CI: [0.98, 1.16]Bayesian repeated measures model
p-value: 27.3395% CI: [0.95, 1.02]Bayesian repeated measures model
p-value: 34.1595% CI: [0.96, 1.03]Bayesian repeated measures model
p-value: 58.4295% CI: [0.98, 1.03]Bayesian repeated measures model
p-value: 5.9395% CI: [0.86, 1.02]Bayesian repeated measures model
p-value: 35.8895% CI: [0.89, 1.08]Bayesian repeated measures model
p-value: 86.4195% CI: [0.97, 1.13]Bayesian repeated measures model
p-value: 13.5295% CI: [0.94, 1.02]Bayesian repeated measures model
p-value: 32.8495% CI: [0.95, 1.03]Bayesian repeated measures model
p-value: 78.0995% CI: [0.98, 1.04]Bayesian repeated measures model
Secondary
Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28
siRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 & D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For SCRD12 & SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).
Time frame: Baseline, Day 12 and Day 28
Population: ITT Population excluding the subject with a pacemaker.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =56, 59 | 0.848 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 56 | 1.028 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58 | 0.934 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.919 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =53, 57 | 1.142 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 56 | 0.829 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.880 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 0.870 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.926 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59 | 1.078 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 1.023 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59 | 0.825 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =57, 58 | 1.073 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 0.849 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 59 | 0.981 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58 | 1.188 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; D12D28 , n =56, 58 | 1.093 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58 | 1.468 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =56, 59 | 0.854 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57 | 1.114 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 58 | 0.964 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.957 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =53, 57 | 1.192 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 1.077 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =55, 59 | 0.820 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57 | 1.284 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 58 | 0.960 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 1.053 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; D12D28 , n=52, 57 | 1.302 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =52, 58 | 1.009 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 0.917 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 1.035 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.961 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58 | 0.755 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 1.060 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 0.781 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =56, 59 | 0.856 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 55 | 1.035 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 58 | 0.954 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.969 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; D12D28 ,n =53, 57 | 1.256 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58 | 0.930 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 0.963 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 0.890 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 0.977 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 57 | 1.349 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 1.032 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 0.982 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 0.892 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56 | 1.063 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.946 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 1.012 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 1.181 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.919 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 0.895 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 1.003 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 0.958 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 0.915 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 1.125 Kpa*s |
| Placebo | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 57 | 0.896 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 0.911 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 57 | 0.908 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 56 | 1.013 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 55 | 0.926 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.944 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.834 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 0.948 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =52, 58 | 1.013 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 57 | 0.904 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 56 | 1.213 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59 | 1.046 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58 | 1.053 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57 | 1.130 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58 | 0.725 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58 | 0.811 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56 | 1.017 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 0.956 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.898 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 1.142 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59 | 0.816 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58 | 0.869 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57 | 1.200 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 0.928 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 0.957 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 1.022 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 0.854 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.880 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 1.234 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 0.914 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 0.929 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | FRC; Scan Trimmed;Region;Total; D12D28 , n =53, 57 | 1.078 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =56, 59 | 0.989 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58 | 1.043 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =53, 57 | 0.903 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59 | 0.977 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58 | 0.885 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57 | 0.896 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =57, 58 | 1.343 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 59 | 1.238 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RML; D12D28 , n =56, 58 | 1.010 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =56, 59 | 1.149 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 58 | 1.134 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =53, 57 | 0.935 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =55, 59 | 1.126 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 58 | 0.985 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Lobes; LLL; D12D28 , n=52, 57 | 0.839 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59 | 1.100 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58 | 0.957 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57 | 0.888 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =56, 59 | 1.112 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 58 | 1.061 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC; Scan Trimmed; Region;Lower; D12D28 ,n =53, 57 | 0.871 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59 | 1.004 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58 | 1.002 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region Central; D12D28 ,n =53, 57 | 0.988 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59 | 1.112 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58 | 0.978 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57 | 0.844 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59 | 1.058 Kpa*s |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28 | TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58 | 0.991 Kpa*s |
p-value: 67.1995% CI: [0.64, 1.33]Bayesian repeated measures random effect
p-value: 44.895% CI: [0.66, 1.61]Bayesian repeated measures random effect
p-value: 59.995% CI: [0.61, 1.46]Bayesian repeated measures random effect
p-value: 70.1295% CI: [0.63, 1.31]Bayesian repeated measures random effect
p-value: 83.9895% CI: [0.54, 1.22]Bayesian repeated measures random effect
p-value: 34.9395% CI: [0.73, 1.57]Bayesian repeated measures random effect
p-value: 32.4595% CI: [0.65, 1.96]Bayesian repeated measures random effect
p-value: 95.3595% CI: [0.46, 1.06]Bayesian repeated measures random effect
p-value: 50.195% CI: [0.66, 1.54]Bayesian repeated measures random effect
p-value: 59.3795% CI: [0.55, 1.6]Bayesian repeated measures random effect
p-value: 87.9995% CI: [0.55, 1.17]Bayesian repeated measures random effect
p-value: 70.8795% CI: [0.59, 1.36]Bayesian repeated measures random effect
p-value: 63.7195% CI: [0.51, 1.6]Bayesian repeated measures random effect
p-value: 65.9995% CI: [0.57, 1.44]Bayesian repeated measures random effect
p-value: 71.9595% CI: [0.6, 1.32]Bayesian repeated measures random effect
p-value: 48.2895% CI: [0.71, 1.43]Bayesian repeated measures random effect
p-value: 61.0695% CI: [0.65, 1.39]Bayesian repeated measures random effect
p-value: 18.0595% CI: [0.82, 1.74]Bayesian repeated measures random effect
p-value: 61.1295% CI: [0.53, 1.61]Bayesian repeated measures random effect
p-value: 64.495% CI: [0.61, 1.41]Bayesian repeated measures random effect
p-value: 38.1295% CI: [0.69, 1.66]Bayesian repeated measures random effect
p-value: 9195% CI: [0.67, 1.08]Bayesian repeated measures random effect
p-value: 94.5295% CI: [0.62, 1.05]Bayesian repeated measures random effect
p-value: 82.1195% CI: [0.72, 1.13]Bayesian repeated measures random effect
p-value: 48.195% CI: [0.64, 1.6]Bayesian repeated measures random effect
p-value: 65.6695% CI: [0.64, 1.36]Bayesian repeated measures random effect
p-value: 11.4695% CI: [0.87, 1.8]Bayesian repeated measures random effect
p-value: 77.295% CI: [0.7, 1.17]Bayesian repeated measures random effect
p-value: 87.3595% CI: [0.66, 1.11]Bayesian repeated measures random effect
p-value: 56.5395% CI: [0.77, 1.25]Bayesian repeated measures random effect
p-value: 7.2995% CI: [0.94, 1.5]Bayesian repeated measures model
p-value: 55.0995% CI: [0.75, 1.28]Bayesian repeated measures model
p-value: 96.4995% CI: [0.61, 1.02]Bayesian repeated measures model
p-value: 14.5495% CI: [0.9, 1.44]Bayesian repeated measures model
p-value: 66.8595% CI: [0.71, 1.25]Bayesian repeated measures model
p-value: 85.7795% CI: [0.7, 1.11]Bayesian repeated measures model
p-value: 8.6795% CI: [0.91, 1.7]Bayesian repeated measures model
p-value: 14.895% CI: [0.84, 1.75]Bayesian repeated measures model
p-value: 45.6995% CI: [0.75, 1.37]Bayesian repeated measures model
p-value: 2.9495% CI: [0.99, 2.06]Bayesian repeated measures model
p-value: 13.9295% CI: [0.85, 1.73]Bayesian repeated measures model
p-value: 86.495% CI: [0.65, 1.13]Bayesian repeated measures model
p-value: 0.8895% CI: [1.06, 2]Bayesian repeated measures model
p-value: 41.2595% CI: [0.75, 1.43]Bayesian repeated measures model
p-value: 99.295% CI: [0.52, 0.94]Bayesian repeated measures model
p-value: 3.4995% CI: [0.98, 1.51]Bayesian repeated measures model
p-value: 73.0995% CI: [0.72, 1.19]Bayesian repeated measures model
p-value: 92.4195% CI: [0.69, 1.06]Bayesian repeated measures model
p-value: 2.2995% CI: [1.01, 1.89]Bayesian repeated measures model
p-value: 23.6795% CI: [0.81, 1.56]Bayesian repeated measures model
p-value: 98.8795% CI: [0.59, 0.96]Bayesian repeated measures model
p-value: 14.595% CI: [0.95, 1.2]Bayesian repeated measures model
p-value: 30.2695% CI: [0.91, 1.18]Bayesian repeated measures model
p-value: 62.8495% CI: [0.89, 1.09]Bayesian repeated measures model
p-value: 2.0695% CI: [1.01, 1.7]Bayesian repeated measures model
p-value: 49.9795% CI: [0.76, 1.32]Bayesian repeated measures model
p-value: 99.4395% CI: [0.62, 0.94]Bayesian repeated measures model
p-value: 1.1795% CI: [1.02, 1.41]Bayesian repeated measures model
p-value: 49.7895% CI: [0.84, 1.18]Bayesian repeated measures model
p-value: 98.6695% CI: [0.73, 0.98]Bayesian repeated measures model
Secondary
Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment
Imaging trachea length and diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length and diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Day 12 and Day 28
Population: ITT Population excluding the subject with a pacemaker.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Length Day 12, n=56, 59 | -1.886 Millimeter (mm) | Standard Deviation 7.6043 |
| Placebo | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Length Day 28, n=56, 58 | -1.434 Millimeter (mm) | Standard Deviation 6.7887 |
| Placebo | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Diameter Day 12, n=56, 59 | -0.247 Millimeter (mm) | Standard Deviation 1.8777 |
| Placebo | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Diameter Day 28, n=56, 58 | -0.261 Millimeter (mm) | Standard Deviation 1.8672 |
| Placebo | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Length Day 12, n=58, 59 | 0.295 Millimeter (mm) | Standard Deviation 4.0608 |
| Placebo | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Length Day 28, n=56, 59 | 0.168 Millimeter (mm) | Standard Deviation 4.5501 |
| Placebo | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Diameter Day 12, n=58, 59 | -0.067 Millimeter (mm) | Standard Deviation 1.0127 |
| Placebo | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Diameter Day 28, n=56, 59 | -0.046 Millimeter (mm) | Standard Deviation 1.024 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Diameter Day 28, n=56, 59 | -0.082 Millimeter (mm) | Standard Deviation 0.5579 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Length Day 12, n=56, 59 | 0.517 Millimeter (mm) | Standard Deviation 6.0882 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Length Day 12, n=58, 59 | -0.663 Millimeter (mm) | Standard Deviation 3.8027 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Length Day 28, n=56, 58 | 0.485 Millimeter (mm) | Standard Deviation 6.6552 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Diameter Day 12, n=58, 59 | -0.056 Millimeter (mm) | Standard Deviation 0.5098 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Diameter Day 12, n=56, 59 | 0.059 Millimeter (mm) | Standard Deviation 1.1657 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Length Day 28, n=56, 59 | -0.495 Millimeter (mm) | Standard Deviation 3.7295 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Diameter Day 28, n=56, 58 | -0.047 Millimeter (mm) | Standard Deviation 1.1522 |
p-value: 2.8995% CI: [1, 1.07]Bayesian repeated measures model
p-value: 8.4995% CI: [0.99, 1.05]Bayesian repeated measures model
p-value: 86.2195% CI: [0.98, 1.07]Bayesian repeated measures model
p-value: 75.295% CI: [0.98, 1.05]Bayesian repeated measures model
p-value: 84.2995% CI: [0.97, 1.01]Bayesian repeated measures model
p-value: 71.0895% CI: [0.98, 1.01]Bayesian repeated measures model
p-value: 34.9395% CI: [0.98, 1.01]Bayesian repeated measures model
p-value: 25.0595% CI: [0.98, 1.01]Bayesian repeated measures model
Secondary
Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment
Imaging trachea length/diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length/diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Day 12 and Day 28
Population: ITT Population excluding the subject with a pacemaker.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Length/Diameter Day 12, n=56 | -0.030 ratio | Standard Deviation 0.7717 |
| Placebo | Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Length/Diameter Day 28, n=56 | -0.017 ratio | Standard Deviation 0.7469 |
| Placebo | Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Length/Diameter Day 12, n=5 | 0.024 ratio | Standard Deviation 0.3602 |
| Placebo | Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Length/Diameter Day 28, n=5 | 0.004 ratio | Standard Deviation 0.3715 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Length/Diameter Day 28, n=5 | -0.006 ratio | Standard Deviation 0.2783 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Length/Diameter Day 12, n=56 | 0.000 ratio | Standard Deviation 0.562 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment | TLC Length/Diameter Day 12, n=5 | -0.023 ratio | Standard Deviation 0.2913 |
| GSK2269557 1000 mcg | Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment | FRC Length/Diameter Day 28, n=56 | 0.059 ratio | Standard Deviation 0.5169 |
p-value: 28.5195% CI: [0.97, 1.06]Bayesian repeated measures model
p-value: 32.1595% CI: [0.97, 1.05]Bayesian repeated measures model
p-value: 66.5195% CI: [0.97, 1.02]Bayesian repeated measures model
p-value: 45.2895% CI: [0.98, 1.03]Bayesian repeated measures model
Secondary
Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28
Change from Baseline in lung lobar volumes was measured at functional residual volume (FRC) and total lung capacity (TLC) scan conditions. Data was collected at longitudinal time points: Day 12 & Day 28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL & LLL) and 5 Regions (Upper, Lower, Central, Distal & Total). For longitudinal time points the baseline is screening. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).
Time frame: Baseline, Day 12 and Day 28
Population: ITT Population excluding the subject with a pacemaker.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RLL Day 28, n =56, 58 | 0.972 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RUL; Day 12, n =56, 57 | 0.983 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RUL Day 28, n =56, 56 | 0.977 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; LUL Day 12, n =56, 59 | 0.974 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes;LUL Day 28, n =56, 58 | 0.980 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RML Day 12, n =55, 58 | 0.981 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RML Day 28, n =56, 57 | 0.972 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RLL Day 12, n =56, 59 | 0.977 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Total Day 28, n =56, 59 | 1.002 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; LLL Day 12, n =55, 59 | 0.968 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; LLL Day 28, n =55, 58 | 0.979 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Upper Day 12, n =56, 59 | 0.980 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Upper Day 28, n =56, 58 | 0.978 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Lower Day 12, n =56, 59 | 0.975 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Lower Day 28, n =56, 58 | 0.975 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Total Day 12, n =56, 59 | 0.975 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Total Day 28, n =56, 58 | 0.976 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RUL; Day 12, n =58, 57 | 1.009 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RUL Day 28, n =56, 57 | 1.005 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; LUL Day 12, n =58, 59 | 1.002 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes;LUL Day 28, n =56, 59 | 1.004 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RML Day 12, n =57, 58 | 0.998 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RML Day 28, n =56, 58 | 0.992 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RLL Day 12, n =58, 59 | 1.010 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RLL Day 28, n =56, 59 | 1.000 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; LLL Day 12, n =57, 59 | 1.008 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; LLL Day 28, n =55, 59 | 1.002 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Upper Day 12, n =58, 59 | 1.005 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC UpperDay 28, n =56, 59 | 1.004 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lower Day 12, n =58, 59 | 1.009 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lower Day 28, n =56, 59 | 1.000 L |
| Placebo | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Total Day 12, n =58, 59 | 1.005 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Total Day 12, n =58, 59 | 0.997 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Total Day 28, n =56, 59 | 1.001 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Total Day 28, n =56, 58 | 1.008 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RUL; Day 12, n =56, 57 | 0.995 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RLL Day 28, n =56, 59 | 1.009 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RUL Day 28, n =56, 56 | 1.017 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RUL; Day 12, n =58, 57 | 0.999 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; LUL Day 12, n =56, 59 | 0.998 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC UpperDay 28, n =56, 59 | 0.999 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes;LUL Day 28, n =56, 58 | 1.017 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RUL Day 28, n =56, 57 | 0.999 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RML Day 12, n =55, 58 | 0.992 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; LLL Day 12, n =57, 59 | 0.989 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RML Day 28, n =56, 57 | 0.996 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; LUL Day 12, n =58, 59 | 0.998 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RLL Day 12, n =56, 59 | 1.004 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lower Day 28, n =56, 59 | 1.003 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; RLL Day 28, n =56, 58 | 1.009 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes;LUL Day 28, n =56, 59 | 0.998 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; LLL Day 12, n =55, 59 | 0.983 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; LLL Day 28, n =55, 59 | 0.996 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Lobes; LLL Day 28, n =55, 58 | 0.991 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RML Day 12, n =57, 58 | 0.988 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Upper Day 12, n =56, 59 | 0.996 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lower Day 12, n =58, 59 | 0.997 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Upper Day 28, n =56, 58 | 1.013 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RML Day 28, n =56, 58 | 0.996 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Lower Day 12, n =56, 59 | 0.994 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Upper Day 12, n =58, 59 | 0.997 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Lower Day 28, n =56, 58 | 1.001 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | TLC Lobes; RLL Day 12, n =58, 59 | 1.005 L |
| GSK2269557 1000 mcg | Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28 | FRC Region; Total Day 12, n =56, 59 | 0.994 L |
p-value: 9.8395% CI: [0.99, 1.07]Bayesian repeated measures model
p-value: 63.0495% CI: [0.97, 1.02]Bayesian repeated measures model
p-value: 32.5195% CI: [0.97, 1.06]Bayesian repeated measures model
p-value: 6.2195% CI: [0.99, 1.08]Bayesian repeated measures model
p-value: 15.9195% CI: [0.98, 1.07]Bayesian repeated measures model
p-value: 6.7395% CI: [0.99, 1.09]Bayesian repeated measures model
p-value: 27.6595% CI: [0.96, 1.07]Bayesian repeated measures model
p-value: 12.1995% CI: [0.98, 1.07]Bayesian repeated measures model
p-value: 11.6295% CI: [0.98, 1.1]Bayesian repeated measures model
p-value: 7.6695% CI: [0.99, 1.1]Bayesian repeated measures model
p-value: 28.8895% CI: [0.96, 1.07]Bayesian repeated measures model
p-value: 28.2895% CI: [0.96, 1.07]Bayesian repeated measures model
p-value: 27.8795% CI: [0.97, 1.05]Bayesian repeated measures model
p-value: 81.3495% CI: [0.97, 1.01]Bayesian repeated measures model
p-value: 21.8795% CI: [0.97, 1.07]Bayesian repeated measures model
p-value: 18.5895% CI: [0.97, 1.07]Bayesian repeated measures model
p-value: 22.2895% CI: [0.98, 1.06]Bayesian repeated measures model
p-value: 10.8695% CI: [0.98, 1.07]Bayesian repeated measures model
p-value: 84.8995% CI: [0.97, 1.01]Bayesian repeated measures model
p-value: 63.7895% CI: [0.97, 1.02]Bayesian repeated measures model
p-value: 69.4295% CI: [0.98, 1.01]Bayesian repeated measures model
p-value: 62.6395% CI: [0.97, 1.02]Bayesian repeated measures model
p-value: 72.5595% CI: [0.96, 1.02]Bayesian repeated measures model
p-value: 36.2895% CI: [0.97, 1.04]Bayesian repeated measures model
p-value: 47.4495% CI: [0.96, 1.04]Bayesian repeated measures model
p-value: 22.9995% CI: [0.97, 1.06]Bayesian repeated measures model
p-value: 85.9595% CI: [0.94, 1.02]Bayesian repeated measures model
p-value: 60.295% CI: [0.96, 1.03]Bayesian repeated measures model
p-value: 69.6795% CI: [0.96, 1.03]Bayesian repeated measures model
p-value: 39.8195% CI: [0.97, 1.04]Bayesian repeated measures model
p-value: 73.0195% CI: [0.97, 1.02]Bayesian repeated measures model
p-value: 48.9795% CI: [0.97, 1.03]Bayesian repeated measures model
Secondary
Change From Baseline in Residual Volume After 28 Days and After 84 Days of Treatment
Residual volume is a lung volume representing the amount of air left in the lungs after a forced exhalation. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval.
Time frame: Baseline, Day 28 and Day 84
Population: ITT Population
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo | Change From Baseline in Residual Volume After 28 Days and After 84 Days of Treatment | Day 28, n=53, 59 | -0.157 L |
| Placebo | Change From Baseline in Residual Volume After 28 Days and After 84 Days of Treatment | Day 84, =47, 54 | -0.113 L |
| GSK2269557 1000 mcg | Change From Baseline in Residual Volume After 28 Days and After 84 Days of Treatment | Day 28, n=53, 59 | 0.022 L |
| GSK2269557 1000 mcg | Change From Baseline in Residual Volume After 28 Days and After 84 Days of Treatment | Day 84, =47, 54 | 0.001 L |
p-value: 0.81795% CI: [-0.216, 0.57]Bayesian repeated measures model
p-value: 0.69795% CI: [-0.324, 0.549]Bayesian repeated measures model
Secondary
Change From Baseline in Specific Conductance (sGaw) After 28 Days and After 84 Days of Treatment
Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).Note: values mentioned as 95% confidence interval below are in fact values of 95% Credible Interval.
Time frame: Baseline, Day 28 and Day 84
Population: ITT Population
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo | Change From Baseline in Specific Conductance (sGaw) After 28 Days and After 84 Days of Treatment | Day 28, n=47, 52 | 0.875 1/KPA*S |
| Placebo | Change From Baseline in Specific Conductance (sGaw) After 28 Days and After 84 Days of Treatment | Day 84, =40, 47 | 0.965 1/KPA*S |
| GSK2269557 1000 mcg | Change From Baseline in Specific Conductance (sGaw) After 28 Days and After 84 Days of Treatment | Day 28, n=47, 52 | 1.024 1/KPA*S |
| GSK2269557 1000 mcg | Change From Baseline in Specific Conductance (sGaw) After 28 Days and After 84 Days of Treatment | Day 84, =40, 47 | 1.075 1/KPA*S |
p-value: 0.96595% CI: [0.988, 1.388]Bayesian repeated measures model
p-value: 0.91395% CI: [0.953, 1.305]Bayesian repeated measures model
Secondary
Change From Baseline in Specific Resistance (sRaw) After 28 Days and After 84 Days of Treatment
sRaw is the measure of specific resistance. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Day 28 and Day 84
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Specific Resistance (sRaw) After 28 Days and After 84 Days of Treatment | Day 28, n= 17, 17 | 0.9734 KPa*s | Standard Deviation 0.45833 |
| Placebo | Change From Baseline in Specific Resistance (sRaw) After 28 Days and After 84 Days of Treatment | Day 84, n=11, 13 | 0.9949 KPa*s | Standard Deviation 0.24484 |
| GSK2269557 1000 mcg | Change From Baseline in Specific Resistance (sRaw) After 28 Days and After 84 Days of Treatment | Day 28, n= 17, 17 | 0.8372 KPa*s | Standard Deviation 0.49176 |
| GSK2269557 1000 mcg | Change From Baseline in Specific Resistance (sRaw) After 28 Days and After 84 Days of Treatment | Day 84, n=11, 13 | 0.8495 KPa*s | Standard Deviation 0.39565 |
Secondary
Change From Baseline in Total Lung Capacity (TLC) After 28 Days and After 84 Days of Treatment
TLC is the maximum amount of air that can fill the lungs. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval.
Time frame: Baseline, Day 28 and Day 84
Population: ITT Population
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo | Change From Baseline in Total Lung Capacity (TLC) After 28 Days and After 84 Days of Treatment | Day 28, n=53, 59 | -0.010 L |
| Placebo | Change From Baseline in Total Lung Capacity (TLC) After 28 Days and After 84 Days of Treatment | Day 84, n=47, 55 | -0.149 L |
| GSK2269557 1000 mcg | Change From Baseline in Total Lung Capacity (TLC) After 28 Days and After 84 Days of Treatment | Day 28, n=53, 59 | -0.155 L |
| GSK2269557 1000 mcg | Change From Baseline in Total Lung Capacity (TLC) After 28 Days and After 84 Days of Treatment | Day 84, n=47, 55 | -0.029 L |
p-value: 0.15195% CI: [-0.42, 0.133]Bayesian repeated measures model
p-value: 0.71295% CI: [-0.305, 0.551]Bayesian repeated measures model
Secondary
Changes From Baseline in Forced Expiratory Volume in One Second (FEV1) Measured Daily
FEV1 is the volume of air that can forcibly be blown out in one second. A triplicate FEV1 measurement were taken daily in the morning before dose administration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Day 28, and Day 84
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Changes From Baseline in Forced Expiratory Volume in One Second (FEV1) Measured Daily | Day 28, n=55, 58 | -70.4 mL | Standard Deviation 43.07 |
| Placebo | Changes From Baseline in Forced Expiratory Volume in One Second (FEV1) Measured Daily | Day 84, n=46, 54 | -83.3 mL | Standard Deviation 49.73 |
| GSK2269557 1000 mcg | Changes From Baseline in Forced Expiratory Volume in One Second (FEV1) Measured Daily | Day 28, n=55, 58 | -72.2 mL | Standard Deviation 41.28 |
| GSK2269557 1000 mcg | Changes From Baseline in Forced Expiratory Volume in One Second (FEV1) Measured Daily | Day 84, n=46, 54 | -22.7 mL | Standard Deviation 46.77 |
p-value: 0.48795% CI: [-118.5, 115.3]Bayesian repeated measures model
p-value: 0.81695% CI: [-73.3, 194.3]Bayesian repeated measures model
Secondary
Changes From Baseline in Peak Expiratory Flow (PEF) Measured Daily
PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Day 28, and Day 84
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Changes From Baseline in Peak Expiratory Flow (PEF) Measured Daily | Day 28, n=54, 57 | -13.12 L/min | Standard Deviation 60.421 |
| Placebo | Changes From Baseline in Peak Expiratory Flow (PEF) Measured Daily | Day 84, n=45, 53 | -0.52 L/min | Standard Deviation 65.374 |
| GSK2269557 1000 mcg | Changes From Baseline in Peak Expiratory Flow (PEF) Measured Daily | Day 28, n=54, 57 | -4.76 L/min | Standard Deviation 57.578 |
| GSK2269557 1000 mcg | Changes From Baseline in Peak Expiratory Flow (PEF) Measured Daily | Day 84, n=45, 53 | -0.85 L/min | Standard Deviation 71.17 |
Secondary
Day 1 Plasma Concentration up to 24 Hours (Hrs) Post-dose
Plasma samples were collected at pre-dose, 5 minutes (min), 3 hrs, and 24 hrs post-dose on Day 1. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Pharmacokinetic (PK) Population: all participants in the Safety Population for whom a PK sample was obtained and analyzed. Safety Population comprises of all participants who were randomized.
Time frame: Pre-dose, 5 min, 3 hrs and 24 hrs
Population: Pharmacokinetic (PK) Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Day 1 Plasma Concentration up to 24 Hours (Hrs) Post-dose | Pre-dose, n=61 | 33.0 pg/mL | — |
| Placebo | Day 1 Plasma Concentration up to 24 Hours (Hrs) Post-dose | 5 min, n=60 | 476.6 pg/mL | Standard Deviation 520.85 |
| Placebo | Day 1 Plasma Concentration up to 24 Hours (Hrs) Post-dose | 3 hrs, n=61 | 553.7 pg/mL | Standard Deviation 326.98 |
| Placebo | Day 1 Plasma Concentration up to 24 Hours (Hrs) Post-dose | 24 hrs, n=20 | 539.0 pg/mL | Standard Deviation 482.76 |
Secondary
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG)
12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF). Clinically non-significant (CN) and Clinically significant (CS) abnormal ECG measurements are presented for Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days)
Population: All Subject Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Screening/ Day 1, n=63, 63 | 45 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Day 12, n=61, 60 | 43 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Day 28, n=58, 60 | 41 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Day 28, n=58, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Day 56, n=55, 56 | 36 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Day 56, n=55, 56 | 1 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Day 84, n=52, 55 | 36 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Day 84, n=52, 55 | 1 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Follow-up/Early Withdraw, n=56, 60 | 35 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Follow-up/Early Withdraw, n=56, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Any Visit Post Baseline, n=63, 62 | 51 Participants |
| Placebo | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Any Visit Post Baseline, n=63, 62 | 3 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Follow-up/Early Withdraw, n=56, 60 | 43 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Screening/ Day 1, n=63, 63 | 40 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Any Visit Post Baseline, n=63, 62 | 51 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Day 12, n=61, 60 | 40 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Day 84, n=52, 55 | 38 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Follow-up/Early Withdraw, n=56, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Day 28, n=58, 60 | 40 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Day 28, n=58, 60 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CS ECG Any Visit Post Baseline, n=63, 62 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) | CN ECG Day 56, n=55, 56 | 39 Participants |
Secondary
Number of Participants With Abnormal Clinical Chemistry Parameters
Clinical Chemistry parameters included Alanine Amino Transferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Calcium (Ca), Glucose, Potassium (K), Sodium (Na), and Total Bilirubin (TBL) at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days)
Population: All Subject Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Day 56, n=55, 56 | 3 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Day 84, n=52, 55 | 5 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Follow-up/Early Withdraw, n=53, 53 | 4 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Follow-up/Early Withdraw, n=53, 53 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Follow-up/Early Withdraw, n=53, 54 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Screening/ Day 1, n=63, 63 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Day 28, n=58, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Day 12, n=61, 60 | 2 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Day 12, n=61, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Day 28, n=58, 60 | 2 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Day 84, n=52, 550 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Day 28, n=58, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium V4 Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Screening/ Day 1, n=63, 63 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Follow-up/Early Withdraw, n=53, 54 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Day 12, n=61, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Day 84, n=52, 55 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Screening/ Day 1, n=63, 63 | 6 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Screening/ Day 1, n=63, 63 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Follow-up/Early Withdraw, n=53, 54 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Day 12, n=61, 60 | 2 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Day 28, n=58,60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Day 28, n=58, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Day 84, n=51, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Follow-up/Early Withdraw, n=53, 54 | 1 Participants |
| Placebo | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Follow-up/Early Withdraw, n=53, 54 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Screening/ Day 1, n=63, 63 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALT Follow-up/Early Withdraw, n=53, 54 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Albumin Follow-up/Early Withdraw, n=53, 53 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High ALP Follow-up/Early Withdraw, n=53, 54 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Screening/ Day 1, n=63, 63 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High AST Follow-up/Early Withdraw, n=53, 54 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Ca Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Ca Follow-up/Early Withdraw, n=53, 53 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Screening/ Day 1, n=63, 63 | 8 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Day 12, n=61, 60 | 6 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Day 28, n=58, 60 | 3 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Day 56, n=55, 56 | 5 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Day 84, n=52, 55 | 3 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Glucose Follow-up/Early Withdraw, n=53, 53 | 6 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Glucose Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Screening/ Day 1, n=63, 63 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium V4 Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Day 84, n=52, 550 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Potassium Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Potassium Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High Sodium Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | Low Sodium Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Day 28, n=58,60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Clinical Chemistry Parameters | High TBL Day 84, n=51, 55 | 0 Participants |
Secondary
Number of Participants With Abnormal Hematology Parameters
Hematology parameter included Hematocrit (HCT), Hemoglobin (HB), Lymphocytes (LC), Platelet Count (PC), Total Neutrophils (TN), and White Blood Cell (WBC) count at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 Days)
Population: All Subjects Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low LC Screening/ Day 1, n=62, 60 | 9 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HB Day 84, n=49, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HB Day 28, n=57, 58 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HB Day 56, n=55, 52 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HCT Screening/Day 1, n=63, 62 | 4 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HCT Day 12, n=60, 58 | 1 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HCT Day 28, n=57, 58 | 1 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HCT Day 56, n=55, 52 | 1 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HCT Day 84, n=49, 53 | 2 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HCT Follow-up/Early Withdraw, n=54, 53 | 4 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HB Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HB Day 12, n=60, 58 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High HB Follow-up/Early Withdraw, n=54, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low LC Day 12, n=59, 58 | 2 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low LC Day 28, n=56, 57 | 3 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low LC Day 56, n=54, 52 | 2 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low LC Day 84, n=48, 50 | 2 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low LC Follow-up/Early Withdraw, n=53, 53 | 1 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High PC Screening/Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High PC Day 12, n=58, 57 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High PC Day 28, n=57, 58 | 1 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High PC Day 56, n=55, 52 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High PC Day 84, n=49, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High PC Follow-up/Early Withdraw, n=54, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low PC Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low PC Day 12, n=58, 57 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low PC Day 28, n=57, 58 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low PC Day 56, n=55, 52 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low PC Day 84, n=49, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low PC Follow-up/Early Withdraw, n=54, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low TN Screening/ Day 1, n=62, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low TN Day 12, n=59, 58 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low TN Day 28, n=56, 57 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low TN Day 56, n=54, 52 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low TN Day 84, n=48, 50 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low TN Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High WBC Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High WBC Day 12, n=56, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High WBC Day 28, n=56, 57 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High WBC Day 56, n=54, 52 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High WBC Day 84, n=48, 50 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | High WBC Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low WBC Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low WBC Day 12, n=56, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low WBC Day 28, n=56, 57 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low WBC Day 56, n=54, 52 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low WBC Day 84, n=48, 50 | 0 Participants |
| Placebo | Number of Participants With Abnormal Hematology Parameters | Low WBC Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low WBC Day 84, n=48, 50 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low PC Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HB Day 84, n=49, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High WBC Screening/ Day 1, n=63, 63 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HB Day 28, n=57, 58 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low PC Day 12, n=58, 57 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low WBC Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HCT Screening/Day 1, n=63, 62 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low PC Day 28, n=57, 58 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HCT Day 12, n=60, 58 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High WBC Day 12, n=56, 56 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HCT Day 28, n=57, 58 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low PC Day 56, n=55, 52 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HCT Day 56, n=55, 52 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low WBC Day 56, n=54, 52 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HCT Day 84, n=49, 53 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low PC Day 84, n=49, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HCT Follow-up/Early Withdraw, n=54, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High WBC Day 28, n=56, 57 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HB Screening/ Day 1, n=63, 63 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low PC Follow-up/Early Withdraw, n=54, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HB Day 12, n=60, 58 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low WBC Day 12, n=56, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HB Follow-up/Early Withdraw, n=54, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High HB Day 56, n=55, 52 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low LC Screening/ Day 1, n=62, 60 | 7 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low TN Screening/ Day 1, n=62, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low LC Day 12, n=59, 58 | 2 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High WBC Day 56, n=54, 52 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low LC Day 28, n=56, 57 | 3 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low TN Day 12, n=59, 58 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low LC Day 56, n=54, 52 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low WBC Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low LC Day 84, n=48, 50 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low TN Day 28, n=56, 57 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low LC Follow-up/Early Withdraw, n=53, 53 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High WBC Day 84, n=48, 50 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High PC Screening/Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low TN Day 56, n=54, 52 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High PC Day 12, n=58, 57 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low WBC Day 28, n=56, 57 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High PC Day 28, n=57, 58 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low TN Day 84, n=48, 50 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High PC Day 56, n=55, 52 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High WBC Follow-up/Early Withdraw, n=53, 53 | 2 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High PC Day 84, n=49, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | Low TN Follow-up/Early Withdraw, n=53, 53 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Hematology Parameters | High PC Follow-up/Early Withdraw, n=54, 53 | 0 Participants |
Secondary
Number of Participants With Abnormal Vital Signs
Vital signs included high and low diastolic and systolic blood presure (BP), and high and low heart rate (HR). Vital signs outside the range of potential clinical importance are presented at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline . Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days)
Population: All Subject Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Abnormal Vital Signs | Low DBP Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High DBP Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High DBP Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High DBP Day 56, n=55, 56 | 1 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High DBP Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High DBP Follow-up/Early Withdraw, n=55, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High DBP Any Visit Post Baseline, n=62, 62 | 1 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low DBP Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low DBP Day 12, n=61, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low DBP Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High DBP Screening/Day 1, n=63, 63 | 1 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low DBP V6 Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low DBP Follow-up/Early Withdraw, n=55, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low DBP Any Visit Post Baseline, n=62, 62 | 1 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High SBP Screening/ Day 1, n=63, 63 | 2 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High SBP Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High SBP Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High SBP Day 56, n=55, 56 | 2 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High SBP Day 84, n=52, 55 | 1 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High SBP Follow-up/Early Withdraw, n=55, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High SBP Any Visit Post Baseline, n=62, 62 | 3 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low SBP Screening/ V1 Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low SBP Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low SBP Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low SBP Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low SBP Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low SBP Follow-up/Early Withdraw, n=55, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low SBP Any Visit Post Baseline, n=62, 62 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High HR Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High HR Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High HR Day 28, n=58, 60 | 2 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High HR Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High HR Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High HR Follow-up/Early Withdraw, n=55, 60 | 1 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | High HR Any Visit Post Baseline, n=62, 62 | 2 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low HR Screening/ Day 1, n=63, 63 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low HR Day 12, n=61, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low HR Day 28, n=58, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low HR Day 56, n=55, 56 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low HR Day 84, n=52, 55 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low HR Follow-up/Early Withdraw, n=55, 60 | 0 Participants |
| Placebo | Number of Participants With Abnormal Vital Signs | Low HR Any Visit Post Baseline, n=62, 62 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High HR Day 56, n=55, 56 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High DBP Screening/Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low SBP Screening/ V1 Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High DBP Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low HR Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High DBP Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low SBP Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High DBP Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High HR Day 84, n=52, 55 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High DBP Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low SBP Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High DBP Follow-up/Early Withdraw, n=55, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low HR Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High DBP Any Visit Post Baseline, n=62, 62 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low SBP Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low DBP Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High HR Follow-up/Early Withdraw, n=55, 60 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low DBP Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low SBP Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low DBP Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low HR Any Visit Post Baseline, n=62, 62 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low DBP Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low SBP Follow-up/Early Withdraw, n=55, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low DBP V6 Day 84, n=52, 55 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High HR Any Visit Post Baseline, n=62, 62 | 3 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low DBP Follow-up/Early Withdraw, n=55, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low SBP Any Visit Post Baseline, n=62, 62 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low DBP Any Visit Post Baseline, n=62, 62 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low HR Day 56, n=55, 56 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High SBP Screening/ Day 1, n=63, 63 | 3 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High HR Screening/ Day 1, n=63, 63 | 2 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High SBP Day 12, n=61, 60 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low HR Screening/ Day 1, n=63, 63 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High SBP Day 28, n=58, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High HR Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High SBP Day 56, n=55, 56 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low HR Follow-up/Early Withdraw, n=55, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High SBP Day 84, n=52, 55 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High HR Day 28, n=58, 60 | 2 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High SBP Follow-up/Early Withdraw, n=55, 60 | 1 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | Low HR Day 12, n=61, 60 | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Abnormal Vital Signs | High SBP Any Visit Post Baseline, n=62, 62 | 2 Participants |
Secondary
Number of Participants With Adverse Events (AE)
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were collected from the start of study treatment until the follow-up contact.
Time frame: From start of IP through the Study Phase (84 days post-dose) (assessed up to follow-up duration of approximately 100 days)
Population: All Subjects Population: all randomized participants who received at least one dose of study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With Adverse Events (AE) | 41 Participants |
| GSK2269557 1000 mcg | Number of Participants With Adverse Events (AE) | 49 Participants |
Secondary
Number of Participants With Treatment Failures
Treatment failure types are presented as: recurrent exacerbations, prolonged treatment of current exacerbation (beyond 14 days), additional treatment with systemic / oral corticosteroids and / or antibiotics, and requirement for invasive mechanical ventilation.
Time frame: 13 weeks
Population: ITT Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Treatment Failures | Prolonged Treatment of current exacerbation | 9 Participants |
| Placebo | Number of Participants With Treatment Failures | Additional treatment with SOC/antibiotics | 6 Participants |
| Placebo | Number of Participants With Treatment Failures | continuation of treatment with SOC/antibiotics | 4 Participants |
| Placebo | Number of Participants With Treatment Failures | Requirement of invasive mechanical ventilation | 0 Participants |
| Placebo | Number of Participants With Treatment Failures | Recurrent exacerbation | 17 Participants |
| GSK2269557 1000 mcg | Number of Participants With Treatment Failures | Requirement of invasive mechanical ventilation | 0 Participants |
| GSK2269557 1000 mcg | Number of Participants With Treatment Failures | Recurrent exacerbation | 13 Participants |
| GSK2269557 1000 mcg | Number of Participants With Treatment Failures | Prolonged Treatment of current exacerbation | 7 Participants |
| GSK2269557 1000 mcg | Number of Participants With Treatment Failures | continuation of treatment with SOC/antibiotics | 3 Participants |
| GSK2269557 1000 mcg | Number of Participants With Treatment Failures | Additional treatment with SOC/antibiotics | 6 Participants |
Secondary
Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment
DLco is diffusing capacity o f the lungs for carbon monoxide and is defined as the extent to which oxygen passes from the air sacs of the lungs into the blood. KCO is the carbon monoxide transfer coefficient. It is an index of the efficiency of alveolar transfer of carbon monoxide. Baseline is defined as the assessment on Day 2 and percent change from Baseline is the post-Baseline value minus Baseline value/100. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Day 28 and Day 84
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment | DLco Day 28, n=53, 56 | -2.783 Percent | Standard Deviation 9.395 |
| Placebo | Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment | DLco Day 84, n=45, 51 | -2.385 Percent | Standard Deviation 9.6016 |
| Placebo | Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment | Kco Day 28, n=53, 55 | -2.745 Percent | Standard Deviation 9.7851 |
| Placebo | Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment | Kco Day 84, n=45, 50 | -2.367 Percent | Standard Deviation 10.2835 |
| GSK2269557 1000 mcg | Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment | Kco Day 84, n=45, 50 | -0.759 Percent | Standard Deviation 8.7801 |
| GSK2269557 1000 mcg | Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment | DLco Day 28, n=53, 56 | -0.687 Percent | Standard Deviation 8.2655 |
| GSK2269557 1000 mcg | Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment | Kco Day 28, n=53, 55 | -0.875 Percent | Standard Deviation 8.0041 |
| GSK2269557 1000 mcg | Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment | DLco Day 84, n=45, 51 | 0.560 Percent | Standard Deviation 9.5434 |
Secondary
Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84
The chronic obstructive pulmonary disease (COPD) assessement test (CAT) and Modified Medical Research Council (MMRC) Dyspnea Scale were completed at the indicated timepoints: Baseline, Day 28 and Day 84. CAT and MMRC scales are prestned as: 1.I never cough/I cough all the time 2.I have no phelgm in my chest at all/My chest is completely full of phelgm 3. My chest does not feel tight at all/My chest feels very tight 4.Walk up hilll or stairs not breathless/Walk up hill or stairs very breathless 5. Not limited doing any home activities/Very limited doing any home activities 6. Confident leaving home/No confident leaving home 7. I sleep soundly/I don't sleep soundly because of my lung condition and 8. I have lots of energy/I have no energy at all. Baseline is defined as the assessment on Day 1. Score 0 indicates not troubled with breathlessness to 4:too breathless. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Day 28 and Day 84
Population: ITT Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | never cough/cough all the time D28, n=58, 60 | -0.4 Scores on a scale | Standard Deviation 1.16 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | never cough/cough all the time D84, n=53, 55 | -0.6 Scores on a scale | Standard Deviation 1.48 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | No phlegm/full of phlegm in chest D28, n=58, 60 | -0.6 Scores on a scale | Standard Deviation 1.26 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | No phlegm/full of phlegm in chest D84, n=53, 55 | -0.8 Scores on a scale | Standard Deviation 1.2 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | No tightness/very tight chest D28, n=58, 60 | -0.2 Scores on a scale | Standard Deviation 1.3 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | No tightness/very tight chest D84, n=53, 55 | -0.1 Scores on a scale | Standard Deviation 1.43 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Hill/stairs nobreathless/breathlessD28, n=58, 60 | -0.5 Scores on a scale | Standard Deviation 0.98 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Hill/stairs nobreathless/breathless D84, n=53, 55 | -0.4 Scores on a scale | Standard Deviation 1.43 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Unlimited/limited home activity D28, n=58, 60 | -0.3 Scores on a scale | Standard Deviation 1.43 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Unlimited/limited home activity D84, n=53, 55 | -0.3 Scores on a scale | Standard Deviation 1.24 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Confident/not confident leave home D28, n=58, 60 | -0.4 Scores on a scale | Standard Deviation 1.24 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Confident/not confident leave homeD84, n=53, 55 | -0.2 Scores on a scale | Standard Deviation 1.49 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Sound sleep/No sound sleep D28, n=58, 60 | -0.4 Scores on a scale | Standard Deviation 1.11 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Sound sleep/No sound sleep D84, n=53, 55 | -0.3 Scores on a scale | Standard Deviation 1.6 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Lot of energy/no energy D28, n=58, 60 | -0.1 Scores on a scale | Standard Deviation 1.46 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Lot of energy/no energy D84, n=53, 55 | -0.2 Scores on a scale | Standard Deviation 1.49 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | CAT Total Score D28, n=58, 60 | -2.9 Scores on a scale | Standard Deviation 6.05 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | CAT Total Score D84, n=53, 55 | -3.0 Scores on a scale | Standard Deviation 7.16 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | MMRC Dyspnoea Score D28, n=58, 60 | -0.4 Scores on a scale | Standard Deviation 0.75 |
| Placebo | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | MMRC Dyspnoea Score D84, n=53, 55 | -0.4 Scores on a scale | Standard Deviation 0.95 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | CAT Total Score D84, n=53, 55 | -3.1 Scores on a scale | Standard Deviation 5.45 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | never cough/cough all the time D28, n=58, 60 | -0.7 Scores on a scale | Standard Deviation 1.14 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Confident/not confident leave home D28, n=58, 60 | -0.1 Scores on a scale | Standard Deviation 1.27 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | never cough/cough all the time D84, n=53, 55 | -0.7 Scores on a scale | Standard Deviation 0.99 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Lot of energy/no energy D84, n=53, 55 | -0.3 Scores on a scale | Standard Deviation 1.25 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | No phlegm/full of phlegm in chest D28, n=58, 60 | -0.3 Scores on a scale | Standard Deviation 1.24 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Confident/not confident leave homeD84, n=53, 55 | -0.3 Scores on a scale | Standard Deviation 1.34 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | No phlegm/full of phlegm in chest D84, n=53, 55 | -0.6 Scores on a scale | Standard Deviation 1.18 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | MMRC Dyspnoea Score D84, n=53, 55 | -0.3 Scores on a scale | Standard Deviation 0.71 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | No tightness/very tight chest D28, n=58, 60 | -0.3 Scores on a scale | Standard Deviation 1.16 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Sound sleep/No sound sleep D28, n=58, 60 | -0.2 Scores on a scale | Standard Deviation 1.3 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | No tightness/very tight chest D84, n=53, 55 | -0.3 Scores on a scale | Standard Deviation 1.34 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | CAT Total Score D28, n=58, 60 | -2.6 Scores on a scale | Standard Deviation 5.13 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Hill/stairs nobreathless/breathlessD28, n=58, 60 | -0.5 Scores on a scale | Standard Deviation 1.08 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Sound sleep/No sound sleep D84, n=53, 55 | -0.3 Scores on a scale | Standard Deviation 1.36 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Hill/stairs nobreathless/breathless D84, n=53, 55 | -0.3 Scores on a scale | Standard Deviation 1.03 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | MMRC Dyspnoea Score D28, n=58, 60 | -0.2 Scores on a scale | Standard Deviation 0.72 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Unlimited/limited home activity D28, n=58, 60 | -0.3 Scores on a scale | Standard Deviation 1.15 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Lot of energy/no energy D28, n=58, 60 | -0.3 Scores on a scale | Standard Deviation 1.22 |
| GSK2269557 1000 mcg | Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84 | Unlimited/limited home activity D84, n=53, 55 | -0.1 Scores on a scale | Standard Deviation 1.39 |
Secondary
Trough Concentration After 12 Days, 28 Days, 56 Days and 84 Days of Treatment
Trough concentrations are presented for Pre-dose Day 12, Pre-dose Day 28, Pre-dose Day 56, and Pre-dose Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Pre-dose Day 12, Day 28, Day 56, and Day 84
Population: PK Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Trough Concentration After 12 Days, 28 Days, 56 Days and 84 Days of Treatment | Pre-dose Day 12, n=57 | 1001.8 pg/mL | Standard Deviation 669.05 |
| Placebo | Trough Concentration After 12 Days, 28 Days, 56 Days and 84 Days of Treatment | Pre-dose Day 28, n=60 | 1028.8 pg/mL | Standard Deviation 798.38 |
| Placebo | Trough Concentration After 12 Days, 28 Days, 56 Days and 84 Days of Treatment | Pre-dose Day 56, n=55 | 1119.8 pg/mL | Standard Deviation 1389.53 |
| Placebo | Trough Concentration After 12 Days, 28 Days, 56 Days and 84 Days of Treatment | Pre-dose Day 84, n=54 | 948.6 pg/mL | Standard Deviation 1078.31 |